Psychedelics: The New Kid on the Block
Prosenjit Ghosh, Avinash Desousa
Annals of Indian Psychiatry 2024 DOI: 10.4103/aip.aip_195_23 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Historical analysis Peer reviewed |
|---|---|
| Key points | The text recounts that these substances were first labeled psychotomimetics in the early twentieth century, later hallucinogens, and that Osmond coined the name psychedelics in 1957 to mean they reveal beneficial properties of the mind. It notes that the notion of beneficial effects met a mixed response among the medical profession until recently. |
Abstract
HISTORY In the early part of twentieth century, these molecules were known as psychotomimetics, meaning that they create a state similar to psychosis. Later on, they were also termed as hallucinogens, but psychedelics usually do not cause hallucinations at a therapeutic dose. The name psychedelics for these substances was first given by Osmond in 1957, meaning that they reveal useful or beneficial properties of the mind. [1] However, the idea that psychedelics can have beneficial effects has had mixed response till recently among the medical fraternity.
Citations in the library
Cites 16
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
and 11 more in the library